spacer
home > ebr > winter 2018 > warning letters
PUBLICATIONS
European Biopharmaceutical Review

Warning Letters

Over the years, communication in the form of published warning letters mentioning requirements for particle characterisation from the FDA has increased. They raise awareness of the control of particle properties of active pharmaceutical ingredients (API) and excipients in manufacturing and the final product (1). Among the wide range of properties that shall be tested, the ICH guidelines topics Q6A and Q8 exemplify particle size, water content, solubility and crystal properties (2). However, they do not seem to be in place everywhere at ingredient suppliers and medicine manufacturers, as underlined by the FDA warning letters. By law, the possibility to carry out validated and approved analysis methods need to be ready before the start of routine production, but may already prove essential in early developing phases. These are needed to set meaningful specifications and later control the out-ofspecification (OOS) in-processes.

Thorough screening and the use of correlated methods ensure the suitable specifications for the solid form, be it organic or biological. Highlighted in this article are the effects of particle properties on manufacturability (flow, size control, general handling), pharmaceutical window distortion (by shift in size distribution and dissolution) and patient safety. This information is very helpful for maintaining control over the manufacturing process. .

In the past five years, FDA warning letters referring to particle characterisation numbered between one and three, but, in the first three quarters of 2017, four had already been sent out. On the basis of ICH guidelines, these intercept the possibility of the manufacturer or resell to import or sell specific products in the regulatory region issuing the letter: the US, which is the most important pharma market today.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Søren Lund Kristensen is the founder and Chief Executive Officer at Particle Analytical, a Danish FDA- and DKMA-approved analysis company operating under cGMP standards for primarily pharma customers worldwide. He is an advisory board member for the Technical University of Denmark. Søren received his education from Royal Veterinary and Agricultural University (now Copenhagen University), Denmark.

Dr Harm Otten is a chemist working at Particle Analytical on a project basis. He received his education from Philipps University, Marburg, Germany and Copenhagen University, Denmark.

spacer
Søren Lund Kristensen
spacer
spacer
spacer
Dr Harm Otten
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PHARM Connect 2019

Life science and business are going to meet at PHARM Connect on the 12-13 of March 2019 in Budapest, Hungary to continue the tradition of providing high calibre, customised professional partnering opportunities for pharma and biotech professionals from Central & Eastern European and beyond and deliver the crucial information they need to excel in their work. The influential annual gathering brings together over 400 global and regional decision-makers, top scientists, industry executives and business development leaders for the ninth time to identify new business opportunities, technologies, state-of-the-art formulation development strategies and to foster exchange of ideas on the role of the sector.
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

 
Industry Events

10th Annual Summit for Clinical Ops Executives

18-21 February 2019, Hyatt Regency Orlando, Florida

Celebrating its 10th successful year, SCOPE Summit 2019 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 19 different conferences, 3 plenary keynote sessions, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations, including...
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement